SEARCH WITHIN CONTENT
VOLUME 20 , ISSUE 7 ( 2016 ) > List of Articles
Franco Diaz, William C. Sasser, Mark A. Law, Jeffrey A. Alten
Keywords : Congenital heart disease, fibrinolysis, shunt thrombosis, tissue plasminogen activator
Citation Information : Diaz F, Sasser WC, Law MA, Alten JA. Systemic thrombolysis with recombinant tissue plasminogen activator for acute life-threatening Blalock-Taussig shunt obstruction. Indian J Crit Care Med 2016; 20 (7):425-427.
License: CC BY-ND 3.0
Published Online: 01-07-2016
Copyright Statement: Copyright © 2016; The Author(s).
Modified Blalock-Taussig shunt (mBTS) obstruction can be life-threatening, especially when it represents the only source of pulmonary blood flow. Current therapeutic options to reverse obstruction include surgical shunt revision/replacement, interventional endovascular procedures including balloon angioplasty and/or stent placement, and a combination of local and systemic thrombolytic therapy. We report two cases of acute mBTS thrombosis successfully treated with systemic recombinant tissue plasminogen activator in infants convalescing after cardiac surgery when the clinical status and resources precluded traditionally described rescue therapies.
© Jaypee Brothers Medical Publishers (P) LTD.